Roberto Veronese has more than 25 years of experience in transforming scientific innovations into market-ready solutions across health and biotechnology sectors. He is the founder and CEO of Accelera BIO, a product advisory firm focused on early- and mid-stage healthcare ventures backed by leading investors including Khosla Ventures and Y Combinator, among others. Through a multi-year engagement with GRAIL, he provided critical product leadership in launching the world’s first multi-cancer early detection test, which analyzes methylation patterns of cell-free DNA and was recognized as one of TIME’s Best Inventions of 2022. He also helped Artera AI bring to market the first AI-based cancer test included in the NCCN guidelines, named one of TIME’s Best Inventions of 2024.
Prior to founding Accelera BIO, Roberto served as Vice President of Product and Design at Helix, where he led the development of the company’s direct-to-consumer genomics strategy and its successful transition to population genomics through partnerships with Mayo Clinic and Renown Health. Before Helix, he was Executive Director at Method, a global experience design firm, where he led the San Francisco office and managed strategic partnerships with digital health and pharmaceutical companies. Previously, he held leadership positions at frog Capgemini and Value Partners Management Consulting, where he advanced product strategy and design for healthcare and biotech clients including Invitae, Complete Genomics, and Pfizer.
Mr. Veronese is an active angel investor and LP at multiple funds. He holds executive education credentials from MIT, Yale School of Management, Stanford School of Medicine, and Columbia Business School. He earned both his BA and MA in Philosophy of Science from the University of Padova in Italy.